UNITED THERAPEUTICS Corp (Form: 4, Received: 09/23/2026 16:31:18)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ☒ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* ROTHBLATT MARTINE A	2. Issuer Name and Ticker or Trading Symbol UNITED THERAPEUTICS Corp [UTHR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chairperson & CEO
(Last) (First) (Middle) C/O UNITED THERAPEUTICS CORPORATION 1000 SPRING STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 9/22/2026
(Street) SILVER SPRING MARYLAND 20910	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip/Postal Code)
UNITED STATES
(Country)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	9/22/2026		M⁽¹⁾		9,500	A	$117.76	333,943	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		240	D	$489.6121 ⁽³⁾	333,703	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		424	D	$490.5378 ⁽⁴⁾	333,279	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		736	D	$491.4469 ⁽⁵⁾	332,543	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		628	D	$492.6678 ⁽⁶⁾	331,915	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		1,645	D	$493.7018 ⁽⁷⁾	330,270	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		1,337	D	$494.6585 ⁽⁸⁾	328,933	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		1,488	D	$495.7662 ⁽⁹⁾	327,445	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		1,484	D	$496.8295 ⁽¹⁰⁾	325,961	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		1,358	D	$497.7257 ⁽¹¹⁾	324,603	I	by Trust ⁽²⁾
Common Stock	9/22/2026		S⁽¹⁾		160	D	$499.0681 ⁽¹²⁾	324,443	I	by Trust ⁽²⁾
Common Stock								40,513	D
Common Stock								166	I	by Spouse
Common Stock								249,108	I	by Trust ⁽¹³⁾
Common Stock								45,596	I	by Trust ⁽¹⁴⁾
Common Stock								8,902	I	by Trust ⁽¹⁵⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$117.76	9/22/2026		M ⁽¹⁾			9,500	⁽¹⁶⁾	3/15/2027	Common Stock	9,500	$0	385,410	I	by Trust ⁽¹⁷⁾

Explanation of Responses:
(1)	This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
(2)	Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
(3)	This transaction was executed in multiple trades at prices ranging from $489.03 to $489.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(4)	This transaction was executed in multiple trades at prices ranging from $490.09 to $491.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(5)	This transaction was executed in multiple trades at prices ranging from $491.09 to $491.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(6)	This transaction was executed in multiple trades at prices ranging from $492.14 to $493.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(7)	This transaction was executed in multiple trades at prices ranging from $493.17 to $494.155. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(8)	This transaction was executed in multiple trades at prices ranging from $494.19 to $495.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(9)	This transaction was executed in multiple trades at prices ranging from $495.20 to $496.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(10)	This transaction was executed in multiple trades at prices ranging from $496.21 to $497.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(11)	This transaction was executed in multiple trades at prices ranging from $497.23 to $498.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(12)	This transaction was executed in multiple trades at prices ranging from $498.31 to $499.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(13)	Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
(14)	Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
(15)	Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
(16)	These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
(17)	Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
ROTHBLATT MARTINE A C/O UNITED THERAPEUTICS CORPORATION 1000 SPRING STREET SILVER SPRING MARYLAND 20910 UNITED STATES	X		Chairperson & CEO

Signatures
/s/ John S. Hess, Jr. under Power of Attorney		9/23/2026
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
* Form 4: SEC 1474 (03-26).